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Fighting vessel dysmorphia to improve
glioma chemotherapy
Marja Lohela1 & Kari Alitalo2,3
High-grade gliomas are aggressive and
abundantly vascular tumors, and as in
most cancer types, blood vessels in
advanced lesions are highly abnormal.
Poor perfusion and vascular leakage in
tumor tissue resulting in hypoxia, necrosis,
and high interstitial fluid pressure can
hamper the efficient delivery of
chemotherapy. Tumor angiogenesis is
known to be supported by host leukocytes
recruited to the tumor microenvironment,
but the mechanisms leading to dysfunc-
tional vascular network formation are
incompletely understood. In this issue of
EMBO Molecular Medicine, Mathivet et al
(2017) present an elegant study, where
longitudinal intravital imaging gives new
insight on how recruitment and polariza-
tion of tumor-associated macrophages
regulate aberrant angiogenesis in experi-
mental gliomas. They show that macro-
phage targeting results in vessel
normalization and improved chemother-
apy response, suggesting that the combi-
nation of these therapeutic modalities
could improve the outcome of glioma
treatment in the clinic.
See also: T Mathivet et al (December 2017)
T he vasculature in solid tumors isalmost always highly abnormal inboth structure and function, with a
tortuous, disorganized and even discontinu-
ous architecture, uneven diameters, and
leakiness arising from features such as
abnormal endothelial junctions, incomplete
pericyte coverage, and altered structural
components. As they grow, tumors become
poorly perfused and therefore hypoxic, and
develop a high interstitial pressure. Metasta-
sis may furthermore be facilitated by
the compromised endothelial integrity
(Carmeliet & Jain, 2011). Anti-angiogenic
therapeutic agents induce pruning of the
excessive and abnormal vascular network,
making the remaining vessels more stable
and functional; this phenomenon is known
as vascular normalization. The perfusion
and oxygenation of tumors is thus
improved, and this may limit invasion and
metastasis as well as improve chemothera-
peutic drug access to the tumor. High-grade
gliomas usually present an extreme case of
tumor angiogenesis, but anti-angiogenic
therapy has so far not lived up to expecta-
tions in this tumor type (Wang et al, 2017).
Different types of host cells in the tumor
microenvironment, notably cancer-asso-
ciated fibroblasts and various myeloid cells,
stimulate angiogenesis and release angio-
genic growth factors (Hanahan & Coussens,
2012). Gliomas release cytokines to recruit
tumor-associated macrophages (TAMs),
which in the case of brain tumors arise
from bone marrow-derived monocytes or
from yolk sac-derived microglia (Quail &
Joyce, 2017). Tumor-associated macro-
phages in turn supply pro-tumorigenic
factors. Large numbers of TAMs and high
levels of the macrophage mitogen colony-
stimulating factor (CSF)-1 correlate with
poor prognosis in most human tumors
(Mantovani et al, 2017). Genetic or thera-
peutic targeting of the CSF-1/CSF-1 receptor
(CSF-1R) pathway in different tumor
models leads to varying degrees of macro-
phage depletion; this has been found to
have direct anti-tumor activity or to potenti-
ate the response to chemotherapy, often
with anti-angiogenic effects (Mantovani
et al, 2017; Lohela et al, 2014). Depletion
of macrophages reduced tumor growth also
in some glioma models (Quail & Joyce,
2017; Zhai et al, 2011), and interestingly,
small molecule inhibition of CSF-1R was
found to dramatically block tumor growth
and progression by downregulating markers
of M2-like polarization of TAMs in a
proneural model of glioblastoma (Pyonteck
et al, 2013). However, in another glioma
model, myeloid cell depletion led to accel-
erated tumor growth (Galarneau et al,
2007).
Intravital microscopy has emerged as an
indispensable tool in studying the complex
tumor microenvironment in situ, with the
possibility of following in real time the
dynamic interactions between cancer cells,
immune cells, vasculature, and the extracel-
lular matrix, and of following tumor growth
and invasion longitudinally via imaging
windows. In the study by Mathivet et al
(2017; see Fig 1 for a graphical summary of
the findings), gliomas arising from intracra-
nially injected spheroids were first imaged
by two-photon microscopy through a cranial
window at 2 weeks postimplantation. The
authors found that at this stage, angiogene-
sis was proceeding in an orderly fashion,
with tip cell-guided sprouting and without
the characteristics of aberrant angiogenesis
normally observed in tumors. However, at
5 weeks, the same tumors displayed abnor-
mal filopodia extension and sprouting along
the stalk of the vessels, and significantly
increased vessel diameters. Searching for the
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reason for the switch in vascular phenotype
during tumor progression, the authors
noticed that bone marrow-derived macro-
phages accumulate in the tumors during this
period, becoming increasingly concentrated
around the tumor blood vessels. Further
analysis showed that also the phenotype of
the TAMs changed: At 2 weeks, their expres-
sion profile resembled that of classically
activated, M1-polarized macrophages. At
5 weeks, most of the TAMs were clustered
in perivascular locations and had the alter-
natively activated M2 phenotype, which is
known to include the VEGF-secreting, highly
angiogenic Tie2-expressing subpopulation
(Mantovani et al, 2017). Indeed, the M2-
type macrophages in late-stage gliomas
expressed VEGF in the immediate vicinity of
endothelial cells. The accumulation of M2
macrophages coincided with an increasingly
abnormal vessel structure also in human
glioma samples.
Mathivet and coworkers then employed
an anti-CSF-1 antibody to target the TAMs in
gliomas (Mathivet et al, 2017). The therapy
reduced TAMs by 50% and resulted in a
dramatic normalization of the vascular
network. Genetic depletion of VEGF from
myeloid cells or administration of soluble
VEGFR1 had the same effect, despite the
presence of normal numbers of TAMs in the
tumors, indicating that macrophage-derived
VEGF is the main culprit for vessel dysmor-
phia in this model. Strikingly, both TAM
depletion and macrophage-specific VEGF
deletion accelerated tumor growth signifi-
cantly, and conversely, treatment with
recombinant CSF-1 delayed glioma growth































Figure 1. Macrophage depletion treatment by targeting CSF-1, in combination with temozolomide chemotherapy, leads to increased glioma cell death (and
improved outcome) in mouse xenografts.
Initially mainly M1 macrophages populate the tumor stroma, and vessels undergo sprouting angiogenesis. Upon tumor progression, M1 to M2 macrophage switch,
perivascular recruitment, and increased production of VEGF occur, and tumor vessels expand, showing vascular dysmorphogenesis. Neutralization of VEGF by using the
soluble extracellular domain of VEGFR1, or depletion of about half of the macrophages by using CSF-1 blocking antibodies, alleviates hypoxia and normalizes tumor vessels,
but tumor size increases. A combination of the CSF-1 neutralizing antibody and the drug of choice, temozolomide, leads to increased apoptosis of glioma cells and improved
survival of the mice.
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The vascular normalization caused by
macrophage targeting presumably allowed
better delivery of oxygen and nutrients to
the tumor. Importantly, however, anti-CSF-1
therapy also seemed to improve the access
of the standard-of-care chemotherapy temo-
zolomide to gliomas, with a significant
increase in median survival when compared
to chemotherapy alone. This finding is
congruent with findings in mammary
tumors, where myeloid cell-specific deletion
of VEGF similarly led to vascular normaliza-
tion and accelerated tumor growth, but
improved the chemotherapy response
(Stockmann et al, 2008). It was not reported
by Mathivet et al (2017) if the anti-CSF-1
treatment also changed the phenotype of the
TAMs that were not depleted, perhaps
downregulating M2-type effectors, as shown
for the small molecule CSFR-1 inhibitor in
the proneural glioblastoma model (Pyonteck
et al, 2013).
A recent meta-analysis of clinical trials in
high-grade gliomas shows that while there is
an overall increase in progress-free survival
with anti-angiogenic therapy, overall survival
is not significantly increased; however, there
is a trend toward better outcome for combi-
nations with chemotherapy when compared
to anti-angiogenic agents alone (Khasraw
et al, 2014; Wang et al, 2017). Macrophage-
targeted therapies may offer an avenue to
disable the tumor-supporting microenviron-
ment more profoundly than specific anti-
vascular strategies. Several clinical trials are
currently ongoing with small molecule inhibi-
tors or the more specific monoclonal antibod-
ies against CSF-1R (Peyraud et al, 2017).
Monotherapy of solid tumors, including
recurrent glioblastoma multiforme, has so far
given disappointing results (Peyraud et al,
2017), and the findings of Mathivet et al
(2017) may offer some explanation for this.
Trials where anti-CSF-1R agents are
combined with chemotherapy, immunother-
apy, or targeted therapy are still ongoing,
with only some very preliminary promising
results (Peyraud et al, 2017), but fighting on
several fronts could be the way forward in
the treatment for aggressive tumors such as
high-grade gliomas.
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